|Articles|September 25, 1998

September 1998 - Special Issue
Volume 4
Issue 2 SP

Device Evaluation and Coverage Policy in Workers' Compensation: Examples from Washington State

Author(s)Gary M. Franklin, MD, MPH, Jami Lifka, BA, Jonathan Milstein, JD

Download PDF: Device Evaluation and Coverage Policy in Workers' Compensation: Examples from Washington State

Articles in this issue

over 27 years ago

Article

Technology Assessment of Medical Devices

over 27 years ago

Article

Technology Assessment, Coverage Decisions, and Conflict: The Role of Guidelines

over 27 years ago

Article

Technology Assessment of Medical Devices at the Center for Devices and Radiological Health

over 27 years ago

Article

Role of Technology Assessment in Health Benefits Coverage for Medical Devices

over 27 years ago

Article

Transmyocardial Laser Revascularization: A Qualitative Systematic Review

over 27 years ago

Article

Use of an Intravenous Contrast Agent (Optison) to Enhance Echocardiography: Efficacy and Cost Implications

over 27 years ago

Article

The Limited State of Technology Assessment for Medical Devices: Facing the Issues

over 27 years ago

Article

Healthcare Technology Assessment: Methods, Framework, and Role in Policy Making

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

June 4th 2026

Device Evaluation and Coverage Policy in Workers' Compensation: Examples from Washington State

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year

Bridging Science and Reality in Diabetes Care